What Is The Best Time Sampling For The Two Direct Oral Anticoagulants, Dabigatran and Rivaroxaban?

被引：0
|
作者：
Douxfils, Jonathan
Classen, Jean-Francois
Baudar, Justine
Devalet, Berangere
Samama, Meyer Michel
Chatelain, Bernard
Dogne, Jean-Michel
Mullier, Francois
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4805
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran: Do We Have an Adequate Test?
    Hoppensteadt, Debra
    Walenga, Jeanine M.
    Cunanan, Josephine
    Iqbal, Omer
    Lewis, Bruce
    Kalodiki, Evi
    Kahn, Stephen
    Fareed, Jawed
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S178 - S178
  • [42] Perioperative complications with new oral anticoagulants dabigatran, apixaban, and rivaroxaban in Mohs micrographic surgery: A retrospective study
    Antia, Camila
    Hone, Natalie
    Gloster, Hugh
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 967 - 968
  • [43] Rivaroxaban- biggest Study Program of all new direct oral Anticoagulants
    van Eickels, Martin
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 : S27 - S27
  • [44] Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial Fibrillation
    Aoyama, Daisetsu
    Miyazaki, Shinsuke
    Hasegawa, Kanae
    Kaseno, Kenichi
    Ishikawa, Eri
    Mukai, Moe
    Miyahara, Kosuke
    Aiki, Takayoshi
    Matsui, Akira
    Yamaguchi, Junya
    Shiomi, Yuichiro
    Tama, Naoto
    Ikeda, Hiroyuki
    Fukuoka, Yoshitomo
    Morishita, Tetsuji
    Ishida, Kentaro
    Uzui, Hiroyasu
    Tada, Hiroshi
    INTERNATIONAL HEART JOURNAL, 2019, 60 (06) : 1315 - 1320
  • [45] COMPARISON OF COSTS AND HEALTHCARE UTILIZATION BETWEEN PATIENTS USING NOVEL ORAL ANTICOAGULANTS (DABIGATRAN & RIVAROXABAN) VERSUS WARFARIN
    Deshpande, C. G.
    Temkin, Willey C.
    Kogut, S.
    Laforge, R.
    VALUE IN HEALTH, 2017, 20 (05) : A268 - A268
  • [46] New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) and Vitamin K Antagonists: Incidence and Treatment Patterns in 2012 in France
    Maura, G.
    Billionnet, C.
    Weill, A.
    Ricordeau, P.
    Alla, F.
    Allemand, H.
    DRUG SAFETY, 2013, 36 (09) : 836 - 836
  • [47] Direct oral anticoagulants: what can we learn?
    Marongiu, Francesco
    Barcellona, Doris
    INTERNAL AND EMERGENCY MEDICINE, 2018, 13 (07) : 989 - 992
  • [48] Direct oral anticoagulants: what can we learn?
    Francesco Marongiu
    Doris Barcellona
    Internal and Emergency Medicine, 2018, 13 : 989 - 992
  • [49] HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN
    Deitelzweig, Steven
    Gupta, Kiran
    Nadkarni, Anagha
    Trocio, Jeffrey
    Lin, Jay
    Lingohr-Smith, Melissa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 805 - 805
  • [50] Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban
    Levi, Marcel
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (02) : 201 - 202
12345